DBV Technologies | DBVT - Sales Revenues


DBV Technologies reported $645K in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amarin USD 49.22M 451K Dec/2025
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
DBV Technologies USD 645K 2.13M Dec/2025
Halozyme Therapeutics USD 481M 104M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Insmed USD 425.49M 119.53M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
United Therapeutics USD 783.3M 1.8M Jun/2026